| Literature DB >> 27275861 |
Miro Kasum1, Kristijan Kurdija2, Slavko Orešković1, Ermin Čehić3, Dinka Pavičić-Baldani1, Lana Škrgatić1.
Abstract
The aim of the review is to analyse the combination of a gonadotrophin releasing hormone (GnRH) agonist with a human chorionic gonadotrophin (hCG) trigger, for final oocyte maturation in in vitro fertilisation (IVF) cycles. The concept being a ''dual trigger'' combines a single dose of the GnRH agonist with a reduced or standard dosage of hCG at the time of triggering. The use of a GnRH agonist with a reduced dose of hCG in high responders demonstrated luteal phase support with improved pregnancy rates, similar to those after conventional hCG and a low risk of ovarian hyperstimulation syndrome (OHSS). The administration of a GnRH agonist and a standard hCG in normal responders, demonstrated significantly improved live-birth rates and a higher number of embryos of excellent quality, or cryopreserved embryos. The concept of the ''double trigger" represents a combination of a GnRH agonist and a standard hCG, when used 40 and 34 h prior to ovum pick-up, respectively. The use of the ''double trigger" has been successfully offered in the treatment of empty follicle syndrome and in patients with a history of immature oocytes retrieved or with low/poor oocytes yield. Further prospective studies are required to confirm the aforementioned observations prior to clinical implementation.Entities:
Keywords: Combined ovulation triggering; GnRH agonist trigger; double trigger; dual trigger; hCG-triggering
Mesh:
Substances:
Year: 2016 PMID: 27275861 DOI: 10.1080/09513590.2016.1193141
Source DB: PubMed Journal: Gynecol Endocrinol ISSN: 0951-3590 Impact factor: 2.260